Shares of Deciphera Pharmaceuticals Inc (DCPH) are trading 25% higher at a price of $16.92 at the time of this writing. The stock is rocketing upwards along with a handful of other biotech high performers, including (SELB) and (CCXI).
The share price is rising because of a strong earnings beat reported yesterday on 8/4. The company report an EPS of -$0.60 which beat analysts expectations by about $0.07.
Deciphera Pharmaceuticals Inc has been trading between a 52-week high of $37.99 and a 52-week low of $6.51. The stock has a market cap of $1.12 Billion.
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST).